Intuitive Surgical (ISRG) Q1 2026 earnings review
Top-Line Acceleration Masked by Cautious Procedure Guidance
Intuitive Surgical delivered a stellar Q1 2026, with revenue accelerating to 23% YoY growth ($2.77B) and Non-GAAP EPS jumping 38% to $2.50. The da Vinci 5 system continues to catalyze a massive upgrade cycle, pushing total installed systems up 12% YoY. However, the forward-looking narrative is more tempered. Despite achieving 17% procedure growth in Q1, management guided FY26 procedure growth down to a midpoint of 14.5%. Combined with persistent tariff headwinds capping margin expansion, the data suggests the hyper-growth phase of the post-pandemic recovery is normalizing, even as the company flexes its financial muscle with a massive $1.1B share repurchase.
🐂 Bull Case
Da Vinci 5 placements remain extremely robust (232 units in Q1). The new platform is driving systemic upgrades, protecting Intuitive's moat, and fueling a 23% surge in high-margin Instruments & Accessories revenue.
The company repurchased 2.3 million shares for $1.1 billion in a single quarter. This is a massive signal of management confidence in future cash flows and helps support EPS growth.
🐻 Bear Case
FY26 guidance for 13.5-15.5% procedure growth sits noticeably below the 17-20% rates achieved throughout FY25 and Q1 2026, signaling that base volume growth is slowing.
Management explicitly baked a 1.0% revenue penalty into their FY26 gross margin guidance due to tariffs, confirming that global trade friction is a structural headwind to profitability.
⚖️ Verdict: ⚪
Neutral. The operational execution is flawless and the bottom line is surging, but guidance implies the steepest growth rates for both procedures and new platforms are beginning to decelerate.
Key Themes
Da Vinci 5 Driving Capital Placements
The rollout of the da Vinci 5 continues to be the primary engine for capital sales. Q1 saw 232 da Vinci 5 placements out of 431 total da Vinci systems (53% mix), up significantly from the 147 dV5 systems placed in Q1 2025. This adoption is successfully driving higher system ASPs and locking hospitals into Intuitive's next-generation digital and hardware ecosystem.
Recurring Revenue Engine Firing on All Cylinders
Instruments and accessories (I&A) revenue grew 23% YoY to $1.69 billion. This was perfectly synchronized with a 12% expansion in the da Vinci installed base (to 11,395 systems) and 16% da Vinci procedure growth, proving that utilization per machine continues to rise. Additionally, a high mix of operating leases (243 systems in Q1) ensures capital revenue converts into durable, long-term recurring cash flow.
Ion Platform Procedure Growth is Decelerating
While management highlighted 'expanded adoption' of the Ion platform, the data tells a story of consistent deceleration. Ion procedure growth has dropped sequentially for five straight quarters: from 58% in 25Q1 down to 39% in 26Q1. At the same time, Q1 placements were relatively stagnant at 52 units (vs 49 a year ago). The hyper-growth phase of the Ion rollout appears to be cooling.
Macro Trade Friction and Tariffs
The macro trade environment remains a material drag on profitability. Management estimates that tariffs currently in effect will negatively impact FY26 non-GAAP gross profit margin by 1.0% of revenue. They further warned that if additional tariffs are implemented, the hit to the financial results could be 'material'. This caps the leverage the company can pull from its 23% top-line growth.
Aggressive Capital Deployment
Intuitive deployed a massive $1.1 billion to repurchase 2.3 million shares in Q1 alone. For context, in the entirety of Q3 2025, they repurchased $1.9 billion. This aggressive stance shrinks the float and provides a heavy backstop to EPS growth, signaling management believes the stock represents a strong value despite anticipated procedure deceleration.
Decelerating Sequential Capital Placements
While YoY growth remains strong, sequential system placements have reversed. Total da Vinci placements fell from 532 in 25Q4 to 431 in 26Q1, and da Vinci 5 placements fell from 303 to 232. While Q1 generally exhibits some negative seasonality compared to Q4 hospital budget flushes, the drop requires monitoring to ensure the dV5 upgrade cycle isn't front-loaded.
Other KPIs
Accelerating shift toward leasing. Of the 431 da Vinci systems placed, 243 were under operating leases (118 usage-based). This compares to 198 leased systems (107 usage-based) out of 367 total placements in 25Q1. This pressures near-term system revenue but builds a highly predictable, high-margin future revenue stream.
Stable and highly profitable. Non-GAAP income from operations surged to $1.08 billion from $767 million a year ago. The company is generating massive operating leverage, growing operating income 40% YoY on 23% revenue growth, efficiently absorbing the margin drag created by tariffs and the dV5 rollout.
Decreased by $1.05 billion during the quarter. The drop was entirely driven by the $1.1 billion share repurchase and an unspecified business acquisition, completely offsetting the massive cash generated from Q1 operations.
Guidance
Decelerating. Q1 2026 printed at 17% growth, and FY25 finished at 18% growth. The new guidance implies a structural slowdown in procedure volume expansion through the remainder of the year. This is the most crucial leading indicator for future instrument and accessory revenue.
Stable. This is essentially flat compared to the 67.8% printed in 26Q1. The range explicitly includes a ~1.0% headwind from tariffs, meaning underlying manufacturing and supply chain efficiencies are improving enough to offset the geopolitical tax.
Stable. This growth rate is well below the current 23% top-line revenue growth rate, virtually guaranteeing continued operating margin expansion and strong EPS beats if revenue holds up.
Key Questions
Drivers of Procedure Deceleration
Your FY26 guidance calls for 13.5-15.5% procedure growth, a notable step down from the 17% seen in Q1 and the 18% seen last year. Is this driven by capacity constraints, macroeconomic headwinds, or structural saturation in key general surgery markets?
Ion Platform Trajectory
Ion procedure growth has decelerated sequentially for five straight quarters, landing at 39% this quarter. Are we beginning to reach a natural ceiling for bronchoscopy penetration, or are hospital capital constraints slowing the expansion of the Ion installed base?
Tariff Mitigation Strategy
With a 1.0% revenue hit from tariffs baked into FY26 margins, what specific supply chain or manufacturing footprint adjustments are actively underway to claw back this margin over the next 12-24 months?
Capital Allocation Shift
You repurchased $1.1 billion in stock this quarter, a massive acceleration. Is this a signal of a structural shift toward more aggressive ongoing capital returns, or a one-time opportunistic deployment?